Evaluating outcomes and side effects of salvage treatment for recurrent breast cancer
A Prospective Registry Study to Evaluate Oncologic Outcomes and Toxicities of Salvage Treatment in Patients With Locoregionally Recurrent Breast Cancer
This study is testing how well salvage treatments work and what side effects they cause in women with recurring breast cancer that hasn't spread to other parts of the body.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 190 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | Female |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Seoul) |
| Trial ID | NCT05933733 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the clinical outcomes and adverse events associated with salvage treatment in patients experiencing locoregional recurrence of breast cancer. It will evaluate disease status, quality of life, and molecular signatures related to treatment resistance through various assessments, including physical examinations, radiologic evaluations, and patient questionnaires. The study will focus on female patients who have previously undergone definitive treatment for breast cancer and are now facing recurrence without distant metastasis.
Who should consider this trial
Good fit: Ideal candidates for this study are female patients aged 18 to 100 who have experienced locoregional recurrence of breast cancer after initial definitive treatment.
Not a fit: Patients who do not meet the eligibility criteria or are not anticipated to comply with the study protocol may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into effective salvage treatment strategies and improve quality of life for patients with recurrent breast cancer.
How similar studies have performed: While there have been studies on salvage treatments for breast cancer, this specific observational approach focusing on outcomes and molecular signatures is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients with age 18 to 100. * Previous standard definitive treatment for initial breast cancer * Locoregional recurrence without distant metastasis * Planned salvage treatment for locoregional recurrence * Informed consent of the participant Exclusion Criteria: \- Not anticipated for complying the study protocol
Where this trial is running
Seoul
- Samsung Medical Center — Seoul, South Korea (Recruiting)
Study contacts
- Principal investigator: Haeyoung Kim — Samsung Medical Center
- Study coordinator: Haeyoung Kim, MD, PhD
- Email: haeyoung0131.kim@samsung.com
- Phone: 82-2-3410-2612
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.